Company Insights

BMY customer relationships

Explore interactive graphBrowse insights index
BMY customer relationship map

Bristol-Myers Squibb — Wholesaler Concentration and Counterparty Footprint

Bristol-Myers Squibb (BMY) monetizes by developing, manufacturing and selling prescription pharmaceuticals and biologics worldwide, with net product sales representing the vast majority of revenue; the company sells primarily through wholesalers, distributors and specialty pharmacies, and collects on relatively short payment terms. This note dissects BMY’s disclosed customer relationships with the largest U.S. wholesalers, the operational constraints those relationships imply, and the investor-level implications for revenue concentration and collection risk. For deeper relationship analytics, visit https://nullexposure.com/.

The headline: three wholesalers move the bulk of U.S. sales

BMY’s 2025 Form 10‑K identifies the three largest U.S. pharmaceutical wholesalers and quantifies their share of U.S. gross revenues, showing meaningful concentration at the wholesaler level that directly affects cash collection and distribution risk. The filings also include machine-readable tags that flag these companies as customer concentration line-items, indicating the company acknowledges counterparty concentration as a material reporting factor.

Cardinal Health, Inc. (as reported)

Cardinal Health accounted for 22% of BMY’s U.S. gross revenues in FY2025. According to the 2025 Form 10‑K, Cardinal’s share was stable versus prior years (22% in 2024, 23% in 2023), highlighting a persistent channel role. (Source: BMY 2025 Form 10‑K)

Cencora, Inc. (as reported)

Cencora represented 29% of U.S. gross revenues in FY2025, unchanged from the prior two years at 29% each. The 10‑K places Cencora as the largest single wholesaler by this metric, underscoring its central role in BMY’s U.S. distribution footprint. (Source: BMY 2025 Form 10‑K)

Cardinal Health Inc (tagged; CAH)

The company’s 10‑K also encodes Cardinal Health in its customer concentration disclosures and tags it within its structured filings, reinforcing Cardinal’s inclusion in BMY’s formal concentration reporting; the filing metadata identifies the legal entity and maps to the CAH ticker. (Source: BMY 2025 Form 10‑K metadata / tagging)

Mckesson Corporation (tagged; MCK)

BMY’s structured filing tags McKesson as a customer concentration item and maps the relationship to the MCK ticker, indicating McKesson’s formal recognition in the company’s concentration disclosures. (Source: BMY 2025 Form 10‑K metadata / tagging)

McKesson Corporation (as reported)

McKesson accounted for 36% of U.S. gross revenues in FY2025, up from 34% in 2024 and 33% in 2023, making it the largest single wholesaler by percentage in 2025 and a primary operational counterparty. (Source: BMY 2025 Form 10‑K)

Cencora (tagged; COR)

Cencora is likewise present in BMY’s structured disclosures and mapped to the COR ticker, confirming the company’s dual presence in narrative and machine-readable portions of the 10‑K. (Source: BMY 2025 Form 10‑K metadata / tagging)

How these relationships shape BMY’s operating model

BMY’s disclosures reveal a clear operating posture driven by channel concentration and short collection cycles. Key company-level signals include:

  • Contracting posture — short-term: Payment terms across markets are typically 30 to 90 days, which creates regular cash flow turnover but limits contractual lock-in with wholesalers. (Company-level evidence in the 2025 10‑K)
  • Counterparty composition — wholesalers and beyond: Products are sold principally to wholesalers, distributors and specialty pharmacies, with lesser direct sales to retailers, hospitals, government agencies and patients. This establishes a distributor-heavy go-to-market structure. (Company-level description in the 10‑K)
  • Geographic footprint — U.S.-weighted but global operations: The U.S. represented 69% of revenues in 2025, with international sales comprising the balance; BMY still operates manufacturing sites across multiple jurisdictions. (Company-level revenue geography in the 10‑K)
  • Materiality and criticality — product sales dominate: Net product sales are more than 95% of total revenues, signifying that any disruption to distribution channels translates directly to revenue and margin pressure. (Company-level note in the 10‑K)
  • Relationship maturity and stage — active and transactional: Customer orders are generally fulfilled within days, producing minimal backlog and signaling an operationally active, transactional distribution model rather than long-term contractual coverage. (Company-level note in the 10‑K)

These characteristics combine into an operating model where large wholesalers act as essential, high-volume counterparties on short payment cycles, producing concentration-driven exposure to a small set of distributors even as manufacturing and geographic diversification support resilience. For a closer read on counterparty exposure and risk signals, go to https://nullexposure.com/.

Investment implications: concentration, collection, and control levers

The broken-down wholesaler percentages imply an investor should focus on three levers:

  • Concentration risk: With McKesson at 36%, Cencora at 29% and Cardinal around 22% of U.S. gross revenues in 2025, BMY depends on a small number of channel partners for the majority of U.S. flows. This concentration is a top-line vulnerability if a wholesaler experiences operational failure, contract renegotiation, or payment distress. (Source: BMY 2025 Form 10‑K)
  • Collection and credit risk: Short payment terms (30–90 days) reduce financing cost but increase exposure to wholesaler credit quality; the 10‑K explicitly notes that wholesaler financial difficulties could delay collections and negatively impact results. (Company-level language in the 10‑K)
  • Operational offset — diversified manufacturing: BMY maintains manufacturing in multiple countries, which reduces single-site operational risk but does not eliminate distribution concentration risk. The company’s global sales footprint tempers regional shocks but keeps U.S. concentration as a critical variable. (Company-level statements in the 10‑K)

Key takeaway: the business is fundamentally product-driven and highly dependent on a small set of wholesalers for U.S. revenue flow; investors should price in concentration and collection dynamics rather than assume broad retail dispersion.

Practical signals for monitoring

Active monitoring should track (a) wholesaler market health and liquidity, (b) changes in the percentage of U.S. gross revenues attributable to each wholesaler in subsequent 10‑Ks or 10‑Qs, and (c) any evolution of payment terms or distribution strategy. The structured tags in the 2025 filing make it straightforward to automate surveillance of these exact relationships and percentages in future filings. For professional-grade relationship monitoring, visit https://nullexposure.com/.

Conclusion

Bristol‑Myers Squibb operates a high-volume, distributor-centric commercial model with clear concentration among three wholesalers that together account for a majority of U.S. gross revenues. The company’s short payment terms and minimal backlog create regular cash conversion but amplify counterparty credit risk when a large wholesaler experiences stress. For investors, the dominant risk is distribution concentration; the dominant operational mitigant is manufacturing and geographic diversification. For continuous tracking of these counterparty exposures and to integrate relationship signals into investment workflows, go to https://nullexposure.com/.